Nuts! Genentech Halts Enrollment In Xolair Peanut Allergy Trial
This article was originally published in The Pink Sheet Daily
The firm, with collaborators Novartis and Tanox, vows to continue development of the new indication for omalizumab.
You may also be interested in...
Genentech will continue to set a "high bar" for acquisitions after buying Xolair partner Tanox for $919 mil., firm says.
Roche will consider requesting a re-examination of the negative decision by the Committee for Medicinal Products for Human Use.